<DOC>
	<DOCNO>NCT00751621</DOCNO>
	<brief_summary>This study continuation study ZLB06_001CR objective assess efficacy , tolerability , safety IgPro , well long-term health-related quality life patient PID .</brief_summary>
	<brief_title>Study Subcutaneous Immune Globulin Patients Requiring IgG Replacement Therapy ( EU Extension Study )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Subjects primary humoral immunodeficiency , namely diagnosis Common variable immunodeficiency ( CVID ) define PanAmerican Group Immunodeficiency ( PAGID ) European Society Immunodeficiencies ( ESID ) , Xlinked agammaglobulinemia ( XLA ) define PAGID ESID , autosomal recessive agammaglobulinemia participate study ZLB06_001CR tolerate IgPro well Written inform consent Hypoalbuminemia , proteinlosing enteropathy , proteinuria ( define total urine protein concentration &gt; 0.2g/L ) Other significant medical condition could increase risk subject Females pregnant , breast feeding planning pregnancy course study Participation study investigational medicinal product within three month prior enrollment , except ZLB06_001CR Evidence uncooperative attitude Any condition likely interfere evaluation IMP satisfactory conduct study Subjects employee investigational site , relatives spouse investigator</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Immune globulin subcutaneous</keyword>
	<keyword>SCIG</keyword>
	<keyword>primary immunodeficiency</keyword>
	<keyword>PID</keyword>
</DOC>